Aura Core: a coming milestoneThe Verisante Core™ device for lung cancer detection currently has a study underway.
Braun said the initial results are promising, with 50 patients already having been scanned. The lung cancer studies require fewer patients than the skin cancer trial because there are fewer variations of lesions to distinguish between. Braun was hopeful the study would conclude within the next 12 to 18 months, but it depends on the flow of patients.
These devices are being developed with leading experts in their fields. The lung cancer study is being headed by Dr. Stephen Lam, MD, FRCPC, professor of medicine at the University of British Columbia, chair of the Lung Tumour Group and leader of the Lung Cancer Prevention Program at the BC Cancer Agency.
...
Braun is anticipating that the next studies will be straightforward. The plan, after the colon cancer study, is to follow with cervical cancer. The prioritization for the devices is based on the need. Lung cancer is the biggest killer, followed by colon and cervical.
Source: (https://bioscienceworld.ca/DetectinginnovationVerisanteandthepathtoitsingeniouscancerdiagnostictool)